240 related articles for article (PubMed ID: 2495353)
1. Vasorelaxant effects of cromakalim in rats are mediated by glibenclamide-sensitive potassium channels.
Cavero I; Mondot S; Mestre M
J Pharmacol Exp Ther; 1989 Mar; 248(3):1261-8. PubMed ID: 2495353
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic and pharmacological evaluation of the vasodilator and vasoconstrictor effects of endothelin-1 in rats.
Le Monnier de Gouville AC; Mondot S; Lippton H; Hyman A; Cavero I
J Pharmacol Exp Ther; 1990 Jan; 252(1):300-11. PubMed ID: 2405151
[TBL] [Abstract][Full Text] [Related]
3. Effects of the K+ channel activators, RP 52891, cromakalim and diazoxide, on the plasma insulin level, plasma renin activity and blood pressure in rats.
Pratz J; Mondot S; Montier F; Cavero I
J Pharmacol Exp Ther; 1991 Jul; 258(1):216-22. PubMed ID: 1906538
[TBL] [Abstract][Full Text] [Related]
4. K+ channel opening mediates the vasorelaxant effects of nicorandil in the intact vascular system.
Cavero I; Pratz J; Mondot S
Z Kardiol; 1991; 80 Suppl 7():35-41. PubMed ID: 1838848
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive and haemodynamic properties of the potassium channel activating (-) enantiomer of cromakalim in animal models.
Clapham JC; Hamilton TC; Longman SD; Buckingham RE; Campbell CA; Ilsley GL; Gout B
Arzneimittelforschung; 1991 Apr; 41(4):385-91. PubMed ID: 1907150
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of endothelin-1 on the vasorelaxant properties of benzopyran and non-benzopyran potassium channel openers.
Lawson K; Barras M; Zazzi-Sudriez E; Martin DJ; Armstrong JM; Hicks PE
Br J Pharmacol; 1992 Sep; 107(1):58-65. PubMed ID: 1422579
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo comparison of two K+ channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide.
Quast U; Cook NS
J Pharmacol Exp Ther; 1989 Jul; 250(1):261-71. PubMed ID: 2501478
[TBL] [Abstract][Full Text] [Related]
8. Possible involvement of ATP-sensitive K+ channels in the relaxant response of dog middle cerebral artery to cromakalim.
Masuzawa K; Asano M; Matsuda T; Imaizumi Y; Watanabe M
J Pharmacol Exp Ther; 1990 Nov; 255(2):818-25. PubMed ID: 2123008
[TBL] [Abstract][Full Text] [Related]
9. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
Katz LB; Giardino EC; Salata JJ; Moore JB; Falotico R
J Pharmacol Exp Ther; 1993 Nov; 267(2):648-56. PubMed ID: 8246137
[TBL] [Abstract][Full Text] [Related]
10. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide.
Grover GJ; McCullough JR; Henry DE; Conder ML; Sleph PG
J Pharmacol Exp Ther; 1989 Oct; 251(1):98-104. PubMed ID: 2507775
[TBL] [Abstract][Full Text] [Related]
11. Glyburide-sensitive K+ channels in cultured rat hippocampal neurons: activation by cromakalim and energy-depleting conditions.
Politi DM; Rogawski MA
Mol Pharmacol; 1991 Aug; 40(2):308-15. PubMed ID: 1715018
[TBL] [Abstract][Full Text] [Related]
12. The antitussive effect of cromakalim in rats is not associated with adenosine triphosphate sensitive K+ channels.
Kamei J; Iwamoto Y; Narita M; Suzuki T; Misawa M; Kasuya Y
Res Commun Chem Pathol Pharmacol; 1993 May; 80(2):201-10. PubMed ID: 8391711
[TBL] [Abstract][Full Text] [Related]
13. Y-27152, a long-acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state.
Nakajima T; Shinohara T; Yaoka O; Fukunari A; Shinagawa K; Aoki K; Katoh A; Yamanaka T; Setoguchi M; Tahara T
J Pharmacol Exp Ther; 1992 May; 261(2):730-6. PubMed ID: 1578381
[TBL] [Abstract][Full Text] [Related]
14. Effects of several potassium channel openers and glibenclamide on the uterus of the rat.
Piper I; Minshall E; Downing SJ; Hollingsworth M; Sadraei H
Br J Pharmacol; 1990 Dec; 101(4):901-7. PubMed ID: 2128195
[TBL] [Abstract][Full Text] [Related]
15. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
Tosaki A; Szerdahelyi P; Engelman RM; Das DK
J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic profiles of YM934, a novel potassium channel opener.
Uchida W; Masuda N; Taguchi T; Shibasaki K; Shirai Y; Asano M; Matsumoto Y; Tsuzuki R; Fujikura T; Takenaka T
J Cardiovasc Pharmacol; 1994 Feb; 23(2):180-7. PubMed ID: 7511745
[TBL] [Abstract][Full Text] [Related]
17. Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents.
Sargent CA; Smith MA; Dzwonczyk S; Sleph PG; Grover GJ
J Pharmacol Exp Ther; 1991 Oct; 259(1):97-103. PubMed ID: 1920138
[TBL] [Abstract][Full Text] [Related]
18. Effects of BRL 34915 (cromakalim) on renal hemodynamics and function in anesthetized dogs.
Hayashi K; Matsumura Y; Yoshida Y; Ohyama T; Hisaki K; Suzuki Y; Morimoto S
J Pharmacol Exp Ther; 1990 Mar; 252(3):1240-6. PubMed ID: 2108239
[TBL] [Abstract][Full Text] [Related]
19. 8-(Diethylamino)-octyl-3,4,5-trimethoxybenzoate inhibits cromakalim-induced 86Rb efflux from the rat aorta.
Lodge NJ; Halaka NN
J Pharmacol Exp Ther; 1993 Jun; 265(3):1399-405. PubMed ID: 8510016
[TBL] [Abstract][Full Text] [Related]
20. Potassium channel blockade and halothane vasodilation in conducting and resistance coronary arteries.
Larach DR; Schuler HG
J Pharmacol Exp Ther; 1993 Oct; 267(1):72-81. PubMed ID: 8229789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
